



MAY 03 2000

TECH CENTER 1600/2900

Box 506/ Gam 1655

10/C

RECEIVED
5/24/00
APR 28/2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Elsa Goulmy

Serial No.: 09/269,250

Examiner: J. Souaya

TECH CENTER 1600/2900

Filed: May 21, 1999

Group Art Unit: 1655

For: METHOD FOR TYPING OF MINOR HISTOCOMPATIBILITY
ANTIGEN HA-1

1185 Avenue of the Americas
New York, New York 10036
April 20, 2000

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

COMMUNICATION IN RESPONSE TO MARCH 24, 2000 OFFICE ACTION

This Communication is submitted in response to the March 24, 2000 Office Action which was issued by the U.S. Patent and Trademark Office in connection with the above-identified application. A response to the March 24, 2000 Office Action is due April 24, 2000. Accordingly, this Communication is being timely filed.

Sequence Listing

Applicant attaches hereto a copy of the Notice regarding sequence disclosures included with the March 24, 2000 Office Action hereto as **Exhibit A**.

Applicant submits herewith a Sequence Listing as **Exhibit B** hereto in compliance with the requirements of 37 C.F.R. §1.824. In addition, applicant submits herewith a computer readable copy of the Sequence Listing on the enclosed computer diskette, which has

RECEIVED

APR 28 2000

TECH CENTER 1600/2000

Elsa Goulmy
Serial No.: 09/269,250
Filed: May 21, 1999
Page 2

the same content as the paper copy attached as **Exhibit B**. Applicant submits as **Exhibit C**, a Statement in accordance with 37 C.F.R. §1.821(f) certifying that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) and submitted in connection with the above-identified application, has the same information which is submitted herewith as **Exhibit B** entitled "Sequence Listing".

Thus, applicant maintains that the application now complies with the requirements of 37 C.F.R. §1.824 and request that the Examiner withdraw this objection.

If any fee is required authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

Jane M. Love

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231.


Jane M. Love 4/20/00
Date
Robert D. Katz
Reg. No. 30,141
Jane M. Love
Reg. No. 42,812

Robert D. Katz
Registration No. 30,141
Jane M. Love
Registration No. 42,812
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

09/269,250

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):



- ☐ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations published at 1114 OG 29 May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7.

Other: _____

Applicant must provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.